The United Kingdom and the United States have forged a key trade agreement that will maintain zero levies on British medicine exports entering the American market.
Agreement Details of the Deal
As part of the deal, the UK has pledged to increase funding on medicines through the National Health Service (NHS). This commitment secures that duties on these key products will stay at nothing for a period of three years.
This deal is in response to earlier warnings to significantly raise import taxes on patented drug products, with potential rates discussed reaching double the cost.
"This deal between the UK strengthens the global environment for cutting-edge drugs and establishes much-needed balance to American-British drug exports," a statement declared.
Trade Significance
Medicines are one of the Britain's largest goods shipped to the US, which is easily the biggest buyer for major British pharmaceutical firms.
Statistics indicate that in the one-year period prior to September, the UK shipped pharmaceutical products worth over eleven billion pounds to the US. This amount accounted for 17.4% of total UK exports in that span.
"This guarantee secures jobs, increases investment and sets the stage for the UK to become a international leader for life sciences," the Business and Trade Secretary stated.
Key UK Commitments
The pact entails several notable pledges from the British government:
- Higher Cost Ceiling: The UK will increase the affordability limit at which it deems new medicines to be prohibitively costly by 25%.
- Increased NHS Spending: There is a aim to increase overall NHS spending on drugs from 0.3% of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The percentage drug companies must pay back to the NHS to prevent overspending will be capped at fifteen percent. In the past, rebates exceeded twenty percent.
Recent Tensions
The pact follows a long-running row between the drug companies and the British authorities over spending levels and approval rates.
The disagreement were intensified by claims that US patients were charged a premium for the equivalent treatments than patients in the other developed nations.
Over the last 18 months, several significant manufacturing plans in the UK have been paused or scrapped, while substantial investments have been directed toward projects in the United States.
The Science Minister publicly accepted that the NHS had to spend more on treatments, noting that its expenditure on drugs had declined as a percentage of its total funding over the last ten years.
